Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer

References

• Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7:105–114. eCollection 2016. PMID:27766137.
   PubMed Web of Science ®Google Scholar
• Yang N, Li S, Li G, Zhang S, Tang X, Ni S, Jian X, Xu C, Zhu J and Lu M. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. 2017;8:3683–3695; doi: 10.18632/oncotarget.12465. PMID:27713136.
   PubMed Web of Science ®Google Scholar
• Chen G, Yang Z, Eshleman JR, Netto GJ and Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int. 2016;2016:9850690. doi: 10.1155/2016/9850690
   PubMed Web of Science ®Google Scholar
• Wulaningsih W, Wardhana A, Watkins J, Yoshuantari N, Repana D, Van Hemelrijck M. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev. 2016;2:CD008593. doi:10.1002/14651858.CD008593.pub3
   PubMedGoogle Scholar
• Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–33. doi:10.1016/j.chembiol.2010.04.012
   PubMed Web of Science ®Google Scholar
• Yu M, Tong X, Qi B, Qu H, Dong S, Yu B, Zhang N, Tang N, Wang L, Zhang C. Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Mol Med Rep. 2014;9:249–54. doi:10.3892/mmr.2013.1762. PMID:24173769.
   PubMed Web of Science ®Google Scholar
• Fujita K, Kubota Y, Ishida H and Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol. 2015;21:12234–48. doi: 10.3748/wjg.v21.i43.12234
   PubMed Web of Science ®Google Scholar
• Hsieh YT, Lin HP, Chen BM, Huang PT and Roffler SR. Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity. PLoS One. 2015;10:e0141088. doi: 10.1371/journal.pone.0141088
   PubMed Web of Science ®Google Scholar
• Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, Maitra A, Wang H, Tian W, Taguchi A and Hanash SM. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015;107. doi:10.1093/jnci/djv132. PMID:26025324,
   PubMedGoogle Scholar
• Uchida K, Otake K, Tanaka K, Hashimoto K, Saigusa S, Matsushita K, Koike Y, Inoue M, Ueeda M, Okugawa Y, Inoue Y, Mohri Y and Kusunoki M. Clinical implications of CES2 RNA expression in neuroblastoma. J Pediatr Surg. 2013;48:502–9. doi: 10.1016/j.jpedsurg.2012.10.004
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Inoue S, Kameyama M, Kanetoshi A, Fujimoto T, Takaoka K, Araya Y and Shida A. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer. 2003;41:187–98.
   PubMed Web of Science ®Google Scholar
• Bar JK, Grelewski P, Noga L, Rabczynski J, Grybos M and Jelen M. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas. Adv Clin Exp Med. 2012;21:35–42.
   PubMed Web of Science ®Google Scholar
• Zhao M and Gjerset RA. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. PLoS One. 2015;10:e0134929. doi: 10.1371/journal.pone.0134929
   PubMed Web of Science ®Google Scholar
• Liu YP, Chen HL, Tzeng CC, Lu PJ, Lo CW, Lee YC, Tseng CH, Chen YL and Yang CN. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells. Breast Cancer Res Treat. 2013;138:383–93. doi: 10.1007/s10549-013-2441-1
   PubMed Web of Science ®Google Scholar
• Lu B, Zhang H, Zhang T, Cai Y, Hu Y, Zheng H and Li B. Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients. Thorac Cancer. 2016;7:486–94. doi:10.1111/1759-7714.12359
   PubMed Web of Science ®Google Scholar
• Silvestris N, Simone G, Partipilo G, Scarpi E, Lorusso V, Brunetti AE, Maiello E, Paradiso A and Mangia A. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen. Int J Mol Sci. 2014;15:15767–77. doi:10.3390/ijms150915767
   PubMed Web of Science ®Google Scholar
• Azzoni C, Bottarelli L, Cecchini S, Ziccarelli A, Campanini N, Bordi C, Sarli L and Silini EM. Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features. Pathol Res Pract. 2014;210:111–7. doi:10.1016/j.prp.2013.11.004
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016;66:7–30. doi:10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Nanji S, Tsang ME, Wei X, Booth CM. Outcomes after repeat hepatic resection for recurrent metastatic colorectal cancer: a population-based study. Am J Surg. 2017;3:1053–1059. doi:10.1016/j.amjsurg.2016.08.014. Epub 2016 Sep 6. PMID:27697193.
   PubMed Web of Science ®Google Scholar
• Digkas E, Kareli D, Chrisafi S, Passadaki T, Mantadakis E, Hatzimichail A, Vargemezis V and Lialiaris T. Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan. CPT-11). Food Chem Toxicol. 2010;48:242–9. doi:10.1016/j.fct.2009.10.007. PMID:19819285.
   PubMed Web of Science ®Google Scholar
• Cercek A, Boucher TM, Gluskin JS, Aguilo A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D'Angelica M and Kemeny NE. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol. 2016;114:655–663. doi:10.1002/jso.24399
   PubMed Web of Science ®Google Scholar
• Meisenberg C, Ashour ME, El-Shafie L, Liao C, Hodgson A, Pilborough A, Khurram SA, Downs JA, Ward SE and El-Khamisy SF. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan. Nucleic Acids Res. 2017;45:1159–1176. doi: 10.1093/nar/gkw1026. PMID:28180300.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14. doi:10.1056/nejm200009283431302
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.
   PubMed Web of Science ®Google Scholar
• Musa F, Blank S and Muggia F. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy. Expert Opin Drug Metab Toxicol. 2013;9:215–24. doi:10.1517/17425255.2013.758249
   PubMed Web of Science ®Google Scholar
• Qiu JG, Shen DM, Huang CJ and Tang JX. [Clinical values of detecting excision repair cross complementing 1 and top-isomerase I in individualized therapies of metastatic colorectal cancer]. Zhonghua Yi Xue Za Zhi. 2013;93:3852–6.
   PubMedGoogle Scholar
• Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK and Seymour MT. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26:2690–8. doi:10.1200/jco.2007.15.5580
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O and Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer. CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–42. doi:10.1016/s0140-6736(07)61086-1
   PubMed Web of Science ®Google Scholar
• Hatfield MJ, Tsurkan L, Garrett M, Shaver TM, Hyatt JL, Edwards CC, Hicks LD and Potter PM. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol. 2011;81:24–31. doi:10.1016/j.bcp.2010.09.001
   PubMed Web of Science ®Google Scholar